“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskIncorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age